Quarterly report pursuant to Section 13 or 15(d)

Business Acquisition (Additional Information) (Details)

v3.23.3
Business Acquisition (Additional Information) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Mar. 29, 2023
Jun. 29, 2023
Sep. 30, 2023
Sep. 30, 2023
Dec. 31, 2022
May 17, 2022
Business Acquisition [Line Items]            
Common stock, par value     $ 0.01 $ 0.01 $ 0.01 $ 0.01
Common stock, shares issued     12,164,753 12,164,753 1,623,913  
Common Stock, Shares, Outstanding     12,164,753 12,164,753 1,623,913  
Preferred stock, par value     $ 0.01 $ 0.01 $ 0.01  
Transaction costs     $ 575 $ 575    
Consideration Paid, Fair Value     9,702 9,702    
Common Stock            
Business Acquisition [Line Items]            
Common stock, shares issued   6,961,867        
Common Stock, Shares, Outstanding   6,961,867        
TeraImmune [Member]            
Business Acquisition [Line Items]            
Acquisition name   TeraImmune, Inc.        
Business acquisition date   Jun. 29, 2023        
TeraImmune [Member] | Common Stock            
Business Acquisition [Line Items]            
Number of escrow shares issued 1,212,185          
EoFlow Co., Ltd [Member]            
Business Acquisition [Line Items]            
Debt issued, outstanding amount     $ 1,239 $ 1,239    
EoFlow Co., Ltd [Member] | Common Stock            
Business Acquisition [Line Items]            
Debt conversion, shares issued       314,282    
EoFlow Co., Ltd [Member] | Preferred Stock            
Business Acquisition [Line Items]            
Debt conversion, shares issued       7,024    
TIT Investor [Member]            
Business Acquisition [Line Items]            
Preferred shares, discounting value, percentage     3.00% 3.00%    
Bondholder [Member]            
Business Acquisition [Line Items]            
Preferred shares, discounting value, percentage     5.00% 5.00%    
Acquisition-related Costs [Member]            
Business Acquisition [Line Items]            
Transaction costs     $ 575 $ 575    
Convertible Common Stock | TeraImmune [Member]            
Business Acquisition [Line Items]            
Number of escrow shares issued   314,282        
Common stock, shares issued   1,000        
Series X Non-Voting Convertible Preferred Stock [Member]            
Business Acquisition [Line Items]            
Number of escrow shares issued     7,024 7,024    
Preferred stock, par value     $ 0.01 $ 0.01 $ 0.01  
Series X Non-Voting Convertible Preferred Stock [Member] | TeraImmune [Member]            
Business Acquisition [Line Items]            
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 27,089.719          
Number of escrow shares issued   7,024        
Series X Preferred Shares            
Business Acquisition [Line Items]            
Preferred shares, discounting value, percentage     15.00% 15.00%